[vc_row full_width=”stretch_row” css=”.vc_custom_1477659332804{margin-top: 50px !important;margin-bottom: 50px !important;padding-top: 50px !important;padding-bottom: 50px !important;}”][vc_column][vc_column_text]

Seald AS is a biotech company developing an innovative live and personalised medical diagnostic for treating solid cancer.

As each patient is unique, so is their cancer. The method is an advanced decision tool based on treatment of patients own live cancer cells that aims to identify the best cancer drug in the optimal dose for each individual, avoiding non-effective cancer treatment which potentially only adds side effects.

Investigations reveal that most cancer drugs do not lead to beneficial treatment effect for several of the cancer patients treated with the drug. These groups of none-responders lack a diagnostic method that reveals which drug to take and which to avoid. Treating individual non-responders with ineffective cancer drug is troublesome from an ethical perspective. For society, facing 20 Mn new cancer patients yearly, treating non-responders is costly, non-effective and lacks sustainability.

Our disease model bile duct cancer, cholangiocarcinoma, is a rare, but very deadly form of cancer. The five year survival is two to five per cent, the mean life expectancy on standard chemotherapy is only 11,5 months. A small number of patients are eligible for surgery, and more than 50 per cent of these relapse. There is  a huge unmet medical need for our diagnostic that pinpoints the right patient to the right drug.

[/vc_column_text][vc_separator color=”custom” border_width=”3″ el_width=”10″ accent_color=”#f47120″][/vc_column][/vc_row][vc_row full_width=”stretch_row” gap=”35″][vc_column width=”1/2″][vc_single_image image=”543″ img_size=”full”][/vc_column][vc_column width=”1/2″][vc_custom_heading text=”Welcome to Seald AS” font_container=”tag:h1|font_size:42px|text_align:left|line_height:62px” use_theme_fonts=”yes”][vc_column_text]Addressing uncertainty. Unravelling cures.

Seald AS is a biotech company developing an innovative personalised diagnostic approach for treating solid cancers, using bile duct cancer as our disease model. Bile duct cancer is a rare, but very deadly form of cancer afflicting three per cent of people with cancer in the digestive system. Utilising a whole new approach, Seald AS aspires to find the right treatment for the individual patient based on a methodology combining molecular biomarkers, DNA sequencing, ex-vivo drug sensitivity analysis, patient own live cancer cells and living xenograft animal models. Together with our research partners Institute of Cancer Research, The Radium Hospital, Seald plan to run the first clinical study at the renowned Norwegian Radium Hospital in 2020.

MORE ABOUT US [/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row” css=”.vc_custom_1477903335821{padding-top: 50px !important;padding-bottom: 50px !important;}”][vc_column width=”1/4″][vc_column_text]

Renowned partners

Recognised scientific actors on board
[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_column_text]

Innovative approach

To quickly identify effective treatment using evidence-based tests using the patients own living cancer cells
[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_column_text]

Unmet medical need

Bile duct cancer is aggressiv and many patients, both with bile duct cancer and cancers in general,  are treated with therapies that do not work
.[/vc_column_text][/vc_column][vc_column width=”1/4″][vc_column_text]

Large, global market

Estimated global pharma market is USD 2,1–4,2 billion, in addition to the markets for diagnostics and platform technology.I
[/vc_column_text][/vc_column][/vc_row][vc_row full_width=”stretch_row_content” gap=”35″ css=”.vc_custom_1489745557282{background-color: #f4f5f6 !important;background-position: 0 0 !important;background-repeat: no-repeat !important;}”][vc_column css=”.vc_custom_1477907239174{background-position: 0 0 !important;background-repeat: no-repeat !important;}”][vc_row_inner equal_height=”yes”][vc_column_inner width=”1/2″ css=”.vc_custom_1513184818581{background-image: url(http://seald.no/wp-content/uploads/2017/12/home_laborant_optimized_blue.jpg) !important;background-position: center !important;background-repeat: no-repeat !important;background-size: cover !important;}”][vc_empty_space height=”60px”][/vc_column_inner][vc_column_inner width=”1/2″ css=”.vc_custom_1489480735736{padding-top: 80px !important;padding-right: 80px !important;padding-bottom: 80px !important;padding-left: 80px !important;}”][vc_empty_space height=”60px”][vc_column_text]


[/vc_column_text][vc_separator color=”custom” align=”align_left” border_width=”3″ el_width=”10″ accent_color=”#f47120″][vc_column_text]

Innovative therapies for bile duct cancer

The company develops novel therapies for bile duct cancer, also called cholangiocarcinoma (CCA). This is done by employing a multidisciplinary approach to developing completely personalised cures, through unraveling both new diagnostics, medications and a new method for personalised treatments.

Clinical trial to start in 2020

Clinical development will be conducted in collaboration with both Norwegian and American clinical research centres, and will be succeeded with an interventional study. These trials will be conducted at the Clinical Cancer Research Unit (Phase I unit) at the Norwegian Radium Hospital, Oslo University Hospital.

[/vc_column_text][vc_empty_space height=”20px”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space height=”80px”][vc_column_text css=”.vc_custom_1513194565677{margin-bottom: 0px !important; text-align: center;}”]

Seald has received grant from

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”661″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”656″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”658″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”659″ img_size=”full” alignment=”center”][/vc_column][/vc_row][vc_row][vc_column][vc_empty_space][vc_column_text css=”.vc_custom_1513194565677{margin-bottom: 0px !important; text-align: center;}”]

Our Research Partners

[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”663″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”660″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”657″ img_size=”full” alignment=”center”][/vc_column][vc_column width=”1/4″ offset=”vc_col-xs-6″][vc_single_image image=”662″ img_size=”full” alignment=”center”][/vc_column][/vc_row][vc_empty_space]